
J&J cancels eczema drug post-$1.25B acquisition
Johnson & Johnson has discontinued its experimental eczema medication after it failed to meet efficacy standards, ending its $1.25 billion investment in the drug.
All articles tagged with #eczema drug

Johnson & Johnson has discontinued its experimental eczema medication after it failed to meet efficacy standards, ending its $1.25 billion investment in the drug.